<DOC>
	<DOCNO>NCT01917695</DOCNO>
	<brief_summary>The aim study establish role neoadjuvant chemotherapy chemo irradiation carcinoma cervix compare result concurrent chemo irradiation term overall survival , disease free survival quality life .</brief_summary>
	<brief_title>Study Early Stage Bulky Cervical Cancers</brief_title>
	<detailed_description>Early stage bulky cancer cervix , ( define FIGO Stages IB2 , IIA2 IIB ) form distinctive subset `` curable '' cervical cancer good 5 year survival rate adequate treatment . Concurrent chemo radiation without salvage surgery present standard care group cervical cancer . However , pelvic recurrence occur , morbidity salvage surgery radiotherapy , especially brachytherapy often high morbidity salvage radiotherapy follow radical surgery . The advantage downsize disease without use brachytherapy tempt open completely new philosophy radical treatment `` curable '' early stage bulky cancer cervix . This approach appeal especially develop country load cervical cancer high radiotherapy ( brachytherapy ) resource scarce . The result two Phase II trial conduct Govt . Royapettah Hospital , Chennai ( Neoadjuvant Chemotherapy follow Radical Hysterectomy : Cisplatin + 5FU vs. Cisplatin +Paclitaxel ) Govt . General Hospital , Chennai ( Neoadjuvant Chemoradiation weekly cisplatin 50 EBRT follow radical Hysterectomy ) one retrospective study ( Preoperative 50 GY EBRT follow Radical Hysterectomy ) show similar response rate acceptable toxicity profile compare concurrent chemoradiation ( EBRT + Brachytherapy+ Chemotherapy ) . Similar study publish elsewhere similar result . With mind plan conduct Phase III Randomised control trial compare Neoadjuvant Chemotherapy + Radical Hysterectomy Neoadjuvant Chemoradiation + Radical Hysterectomy concurrent chemoradiation subset cervical cancer</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Patients histologically confirm bulky cervical Squamous cell carcinoma ( FIGO stage IB2 , II A2 , IIB ) . 2 . Age 1860 year 3 . Karnofsky performance status ≥70 % ; ECOG PS ≤ 2 1 . Nonsquamous Histologies 2 . Other systemic disease , comorbidities preclude full participation study 3 . Concomitant treatment experimental drug 4 . Pregnant nursing woman 5 . Previous concomitant malignant disease nonmelanoma skin cancer 6 . Previous radiation pelvis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Bulky cervical cancer</keyword>
	<keyword>Neoadjuvant Chemotherapy</keyword>
	<keyword>Neoadjuvant Chemoradiotherapy</keyword>
</DOC>